1. Data on file. Warner Chilcott (US), LLC. Rockaway, NJ.
2. Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 mg (Loestrin 24 Fe). Contraception. 2007;75(1):16-22.
Important Safety Information about Loestrin® 24 Fe:
Loestrin
® 24 Fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives (OCs) as a method of contraception.
Patients should be counseled that OCs do not protect against HIV infection and other sexually transmitted diseases. The use of OCs is associated with increased risks of several serious conditions including venous and arterial thrombotic and thromboembolic events (such as myocardial infarction, thromboembolism, stroke), hepatic neoplasia, gallbladder disease, and hypertension.
Cigarette smoking increases the risk of serious cardiovascular side effects, especially in women over 35. Women who use OCs are strongly advised not to smoke.
The most frequent adverse events reported in clinical trials include headache, vaginal candidiasis, upper respiratory infection, nausea, menstrual cramps, breast tenderness, sinusitis, vaginitis (bacterial), abnormal cervical smear, acne, urinary tract infection, mood swings, weight gain, vomiting, and metrorrhagia.
For further safety and other information please see the
Full Prescribing Information.